<DOC>
	<DOCNO>NCT00210691</DOCNO>
	<brief_summary>The purpose study document long-term safety tolerability risperidone , formulate long-acting injectable , treatment patient schizophrenia schizoaffective disorder ; addition , evaluate long-term effectiveness long-acting risperidone effect quality life</brief_summary>
	<brief_title>A Study Long-acting Injectable Risperidone Treatment Patients With Schizophrenia Schizoaffective Disorder</brief_title>
	<detailed_description>Although many schizophrenia patient currently take oral antipsychotic medication , estimate 75 % difficulty adhere daily oral regimen . Long-acting injectable formulation may eliminate need daily medication enhance patient compliance treatment regimen . This safety study extension randomize , double-blind , multicenter , parallel group study investigate effectiveness safety risperidone inject intramuscularly patient schizophrenia schizoaffective disorder . The present open-label study evaluate 3 different dos formulation risperidone injected muscle 2 week interval least 1 year patient condition . Assessments effectiveness include Clinical Global Impression ( CGI ) overall severity illness scale . Quality life assess SF-36 Health Survey . Safety evaluation include incidence adverse event , physical examination , evaluation injection site , clinical laboratory test , electrocardiogram ( ECGs ) , Extrapyramidal Symptom Rating Scale ( ESRS ) , scale assess muscle tone , gain , abnormal movement . Injections every 2 week least 1 year , begin 25milligrams [ mg ] increase 50mg 75mg ( maximum dose ) . Dosages may increase decreased investigator 's discretion . During first 3 week , risperidone tablet ( 2mg ) daily supplement injectable risperidone .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Patients must complete doubleblind study ( RISUSA121 ) withdrawn study safety reason due worsen condition determine result CGI diagnosis schizophrenia schizoaffective disorder accord criterion Diagnostic Statistical Manual Mental Disorders , 4th edition ( DMS IV ) otherwise healthy basis physical examination , medical history , electrocardiogram , blood biochemistry hematology test , urinalysis . Known intolerance , sensitivity , serious adverse event , unresponsiveness risperidone diagnosis DMS IV Axis I condition schizophrenia schizoaffective disorder diagnosis substance abuse dependence use psychostimulants antipsychotic medication risperidone know disease central nervous system ( stroke , Parkinson 's Disease , Huntington 's Disease , Alzheimer 's Disease , cancer ) pregnant nursing female , lack adequate contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>intramuscular injection</keyword>
	<keyword>psychotropic agent</keyword>
	<keyword>long-acting risperidone</keyword>
</DOC>